A citation-based method for searching scientific literature

Hale M Tasyurek, Hasan Ali Altunbas, Mustafa Kemal Balci, Salih Sanlioglu. Diabetes Metab Res Rev 2014
Times Cited: 53







List of co-cited articles
324 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
13

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
13


Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
931
9

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Juris J Meier, Julio Rosenstock, Agnès Hincelin-Méry, Christine Roy-Duval, Astrid Delfolie, Hans-Veit Coester, Bjoern A Menge, Thomas Forst, Christoph Kapitza. Diabetes Care 2015
165
9

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
9

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
759
9

Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation.
Diana L Williams, Denis G Baskin, Michael W Schwartz. Diabetes 2006
138
7

The glucagon-like peptides.
T J Kieffer, J F Habener. Endocr Rev 1999
759
7

Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
Filip K Knop, Tina Vilsbøll, Patricia V Højberg, Steen Larsen, Sten Madsbad, Aage Vølund, Jens J Holst, Thure Krarup. Diabetes 2007
220
7


Clinical utility of insulin and insulin analogs.
Ahter D Sanlioglu, Hasan Ali Altunbas, Mustafa Kemal Balci, Thomas S Griffith, Salih Sanlioglu. Islets 2013
21
19

Insulin gene therapy from design to beta cell generation.
Ahter D Sanlioglu, Hasan Ali Altunbas, Mustafa Kemal Balci, Thomas S Griffith, Salih Sanlioglu. Expert Rev Mol Med 2012
11
36

Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.
Mahesh M Umapathysivam, Michael Y Lee, Karen L Jones, Christopher E Annink, Caroline E Cousins, Laurence G Trahair, Chris K Rayner, Marianne J Chapman, Michael A Nauck, Michael Horowitz,[...]. Diabetes 2014
79
7

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
7


Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Kathleen M Dungan, Santiago Tofé Povedano, Thomas Forst, José G González González, Charles Atisso, Whitney Sealls, Jessie L Fahrbach. Lancet 2014
282
7

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Richard M Bergenstal, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter. Lancet 2010
441
7

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao, Marilyn K Boardman, Mark Fineman,[...]. Lancet 2013
343
7

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
947
7

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
7

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.
Michael A Nauck, Guido Kemmeries, Jens J Holst, Juris J Meier. Diabetes 2011
216
7

Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis.
T Edholm, M Degerblad, P Grybäck, L Hilsted, J J Holst, H Jacobsson, S Efendic, P T Schmidt, P M Hellström. Neurogastroenterol Motil 2010
95
7

GIP and GLP-1, the two incretin hormones: Similarities and differences.
Yutaka Seino, Mitsuo Fukushima, Daisuke Yabe. J Diabetes Investig 2010
288
7


Rate limiting steps of AAV transduction and implications for human gene therapy.
S Sanlioglu, M M Monick, G Luleci, G W Hunninghake, J F Engelhardt. Curr Gene Ther 2001
62
5


A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
5

Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy.
Jason M Tonne, Toshie Sakuma, Michael C Deeds, Miguel Munoz-Gomez, Michael A Barry, Yogish C Kudva, Yasuhiro Ikeda. Dis Model Mech 2013
39
7

Molecular mechanisms of death ligand-mediated immune modulation: a gene therapy model to prolong islet survival in type 1 diabetes.
Ahter Dilsad Sanlioglu, Thomas S Griffith, Abdulkadir Omer, Ercument Dirice, Ramazan Sari, Hasan Ali Altunbas, Mustafa Kemal Balci, Salih Sanlioglu. J Cell Biochem 2008
18
16

Therapeutic potential of VIP vs PACAP in diabetes.
Ahter D Sanlioglu, Bahri Karacay, Mustafa Kemal Balci, Thomas S Griffith, Salih Sanlioglu. J Mol Endocrinol 2012
30
10


First-generation adenovirus vectors shorten survival time in a murine model of sepsis.
Kevin Doerschug, Salih Sanlioglu, Dawn M Flaherty, Rebecca L Wilson, Timur Yarovinsky, Martha M Monick, John F Engelhardt, Gary W Hunninghake. J Immunol 2002
25
12

Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats.
Ercument Dirice, Ahter Dilsad Sanlioglu, Sevim Kahraman, Saffet Ozturk, Mustafa Kemal Balci, Abdulkadir Omer, Thomas S Griffith, Salih Sanlioglu. Hum Gene Ther 2009
21
14

GLP-1 gene delivery for the treatment of type 2 diabetes.
Seungjoon Oh, Minhyung Lee, Kyung Soo Ko, Suna Choi, Sung Wan Kim. Mol Ther 2003
38
7

Ghrelin enhances appetite and increases food intake in humans.
A M Wren, L J Seal, M A Cohen, A E Brynes, G S Frost, K G Murphy, W S Dhillo, M A Ghatei, S R Bloom. J Clin Endocrinol Metab 2001
5


Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
William C Knowler, Elizabeth Barrett-Connor, Sarah E Fowler, Richard F Hamman, John M Lachin, Elizabeth A Walker, David M Nathan. N Engl J Med 2002
5

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
William C Knowler, Sarah E Fowler, Richard F Hamman, Costas A Christophi, Heather J Hoffman, Anne T Brenneman, Janet O Brown-Friday, Ronald Goldberg, Elizabeth Venditti, David M Nathan. Lancet 2009
5


Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
906
5

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
789
5

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Alan Garber, Robert Henry, Robert Ratner, Pedro A Garcia-Hernandez, Hiromi Rodriguez-Pattzi, Israel Olvera-Alvarez, Paula M Hale, Milan Zdravkovic, Bruce Bode. Lancet 2009
771
5

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Julio Rosenstock, Vivian A Fonseca, Jorge L Gross, Robert E Ratner, Bo Ahrén, Francis C C Chow, Fred Yang, Diane Miller, Susan L Johnson, Murray W Stewart,[...]. Diabetes Care 2014
166
5

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
M Pinget, R Goldenberg, E Niemoeller, I Muehlen-Bartmer, H Guo, R Aronson. Diabetes Obes Metab 2013
98
5



Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Bernard Zinman, John Gerich, John B Buse, Andrew Lewin, Sherwyn Schwartz, Philip Raskin, Paula M Hale, Milan Zdravkovic, Lawrence Blonde. Diabetes Care 2009
622
5


Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.